Medigene AG (Medigene AG) Research & Development : $12.55 Mil (TTM As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Medigene AG Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Medigene AG's Research & Development for the six months ended in Dec. 2023 was $6.94 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was $12.55 Mil.

Medigene AG Research & Development Historical Data

The historical data trend for Medigene AG's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigene AG Research & Development Chart

Medigene AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Research & Development

Get a 7-Day Free Trial

25.14

27.08

14.46

30.19

12.59

Medigene AG Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Research & Development	Get a 7-Day Free Trial															7.33	3.87	26.32	5.62	6.94

Medigene AG Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $12.55 Mil.

Medigene AG (OTCPK:MDGEF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Medigene AG Research & Development Related Terms

Thank you for viewing the detailed overview of Medigene AG's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Medigene AG (Medigene AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigene AG (OTCPK:MDGEF) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

MDG1:Germany MDG1:Austria

Address

Lochhamer Strasse 11, Martinsried, Planegg, BY, DEU, 82152

Website

https://www.medigene.com

Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.

Medigene AG (Medigene AG) Headlines

From GuruFocus

Roivant and Sinovant Launch Cytovant Sciences in Partnership with Medigene to Develop Cellular Therapies in Asia

By PRNewswire PRNewswire • 04-04-2019